139060-02-9

Basic information

• Product Name: Benzonitrile, 2-bromo-, N-oxide
• CAS NO: 139060-02-9
• Molecular Formula: C7H4BrNO
• Molecular Weight: 198.019
• Mol File: 139060-02-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 2-bromo-, N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 2-bromo-, N-oxide(139060-02-9)
• EPA Substance Registry System: Benzonitrile, 2-bromo-, N-oxide(139060-02-9)

Safety Data

• Hazardous Substances Data: 139060-02-9(Hazardous Substances Data)

Upstream product

• 38435-47-1 2-bromo N-hydroxybenzimidoyl chloride 
• 6630-33-7 ortho-bromobenzaldehyde 
• 34158-72-0 2-bromobenzaldehyde oxime 

Downstream Products

• 1620919-39-2 3-(2-bromophenyl)-5-phenyl-4,5-dihydroisoxazole 
• 1186630-08-9 (2-bromophenyl)-spiro-isoxazolinyl parthenin 
• 144835-59-6 (3aR,6aS)-3-(2-Bromo-phenyl)-5-(3,5-dichloro-phenyl)-6a-methyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-97-2 (3aR,6aS)-3-(2-Bromo-phenyl)-5-(3,5-dichloro-phenyl)-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 

Relevant articles and documents

Dibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors

α-Glucosidase inhibition is a valid approach for controlling hyperglycemia in diabetes. In the current study, new molecules as a hybrid of isoxazole and dibenzazepine scaffolds were designed, based on their literature as antidiabetic agents. For this, a series of dibenzazepine-linked isoxazoles (33–54) was prepared using Nitrile oxide-Alkyne cycloaddition (NOAC) reaction, and evaluated for their α-glucosidase inhibitory activities to explore new hits for treatment of diabetes. Most of the compounds showed potent inhibitory potency against α-glucosidase (EC 3.2.1.20) enzyme (IC50 = 35.62 ± 1.48 to 333.30 ± 1.67 μM) using acarbose as a reference drug (IC50 = 875.75 ± 2.08 μM). Structure-activity relationship, kinetics and molecular docking studies of active isoxazoles were also determined to study enzyme-inhibitor interactions. Compounds 33, 40, 41, 46, 48–50, and 54 showed binding interactions with critical amino acid residues of α-glucosidase enzyme, such as Lys156, Ser157, Asp242, and Gln353.

Design and synthesis of spiro derivatives of parthenin as novel anti-cancer agents

Several novel spiro derivatives of parthenin (1) have been synthesized by the dipolar cycloaddition using various dipoles viz; benzonitrile oxides, nitrones and azides with exocyclic double bond of C ring (α-methylene- γ-butyrolactone). Majority of the compounds exhibited improved anti-cancer activity compared to the parthenin, when screened for their in vitro cytotoxicity against three human cancer cell lines viz., SW-620, DU-145 and PC-3. In vivo screening of select analog revealed improved anti-cancer activity with low mammalian toxicity as compared to parthenin. The results of the cytotoxicity pattern of these derivatives reveals the SAR of these sesquiterpinoid lactones and possible role of α,β-unsaturated ketone of parthenin in inhibiting NF-kB. A mechanistic correlation of anti-cancer activity along with in vivo and western blotting experiments has been described.